Zoar Limited filed a Form 6-K on November 18, 2026, disclosing the completion of its previously announced business combination and the commencement of trading of its ordinary shares.
Key Highlights
- Business combination consummated: The merger and share exchange was completed on November 17, 2026, according to the filing.
- Parties involved: The transaction involved Zoar Limited, Impact Biomedical Inc., Zoar Labs Limited, Dr Ashleys Nevada Sub, Inc., and Kanas Visvanats, per the filing.
- Original agreement date: The merger and share exchange agreement was dated as of June 21, 2025, as amended, the filing states.
- Trading commencement: The company's ordinary shares are expected to begin trading on NYSE American under the ticker symbol "ZOAR" on November 18, 2026, as disclosed in the filing.
- Press release furnished: A press release announcing the completion of the business combination and commencement of trading was furnished as Exhibit 99.1 to the filing.
Zoar Limited Closes Merger and Prepares for NYSE American Debut
According to the Form 6-K filed with the U.S. Securities and Exchange Commission, Zoar Limited consummated the previously announced business combination on November 17, 2026. The filing identifies the transaction as having been carried out pursuant to a merger and share exchange agreement originally dated June 21, 2025, and subsequently amended. The parties to the agreement, as listed in the filing, are Zoar Limited, Impact Biomedical Inc., Zoar Labs Limited, Dr Ashleys Nevada Sub, Inc., and Kanas Visvanats.
The filing discloses that, in connection with the completion of the business combination, the company's ordinary shares are expected to commence trading on the NYSE American under the ticker symbol "ZOAR" on November 18, 2026. NYSE American:ZOAR is the exchange and symbol as stated in the filing. The filing was signed by Kanans Visvanats, identified as Chief Executive Officer of Zoar Limited, and is dated November 18, 2026.
The company issued a press release on November 18, 2026, announcing the completion of the business combination and the commencement of trading. That press release was furnished as Exhibit 99.1 to the filing. Zoar Limited is a foreign private issuer headquartered at 1504, 15th Floor, Peninsula Square, 18 Sung On Street, Hung Hom, Kowloon, Hong Kong, as listed in the filing, and files its annual reports under Form 20-F.
What Was Disclosed
Zoar Limited reported in a Form 6-K that it completed its merger and share exchange business combination on November 17, 2026, and that its ordinary shares are expected to begin trading on NYSE American under the symbol "ZOAR" on November 18, 2026.



Please wait processing your request...